Understanding Xpovio (selinexor)

Xpovio® (selinexor) is a selective inhibitor of nuclear export (SINE) compound. In 2019, Xpovio became the first medication in this drug class to receive approval from the U.S. Food and Drug Administration (FDA). Xpovio was initially used for the treatment of relapsed/refractory multiple myeloma (RRMM) in combination with dexamethasone [Xd] or with Velcade® (bortezo­mib) + dexamethasone [XVd]. In 2024, Xpovio is also listed in the National Comprehensive Cancer Network (NCCN) Guidelines for myeloma in combinations with Kyprolis® (carfilzomib) [XKd] or Pomalyst® (pomalidomide) [XPd] or Darzalex® (daratumumab) [XDd, DXd, or Dara-Xd].